Related Experiment Video
Updated: Jan 10, 2026

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
Published on: April 19, 2019
Cardiometabolic risk reduction with digital twinning in patients with type 2 diabetes
Seyed Arsalan Seyedi1, Juan P González-Rivas2, Pranav Mellacheruvu3
1Endocrinology and Metabolism Research Center (EMRC), School of Medicine, Vali-Asr Hospital, Imam Khomeini Hospital, P.O. Box 13145784, Tehran, Iran. arsalanseyyedi5@gmail.com.
Abstract:
Digital twin (DT) technology-real-time, data-driven virtual models of individuals-offers transformative potential in managing cardiometabolic-based chronic disease (CMBCD). The novel CMBCD model configures a progression from interacting adiposity, dysglycemia, hypertension, dyslipidemia, and residual drivers to certain cardiovascular diseases (CVDs) such as atherosclerosis, heart failure, and atrial fibrillation. Insulin resistance and type 2 diabetes (T2D) are central to this cascade, requiring management tactics where DT serves as a precision-medicine tool. A systematic search across PubMed, Embase, Web of Science, Scopus, and Cochrane identified 12 eligible studies (retrospective cohort, randomized clinical trials, and frameworks) to explore the role of DT in T2D and CMBCD. Due to data duplication and lack of homogeneity, meta-analysis was not feasible, prompting this narrative synthesis. DT-guided benefits were identified across the CMBCD spectrum: (1) adiposity - body mass index reduction by 1.8 kg/m² with decreased visceral adiposity; (2) dysglycemia - hemoglobin A1c reduction as much as 1.8% with 89% achieving glycemic targets, as well as fewer medications used, time-in-range (TIR) improved 69.7% to 86.9%, and time-above-range decreased; (3) hypertension - normal blood pressure cases increased from 46.4% to 63.1% and outperforming standard care; (4) dyslipidemia - triglycerides decreased 18.8% and high density lipoprotein (HDL) increased 6.8%; (5) residual - metabolic dysfunction-associated steatotic liver disease improvements; and (6) complications - improved chronic kidney disease, retinopathy, and cataract prediction, comprehensive CVD risk reduction, and medication de-escalation. In sum, DT appears promising for comprehensive and personalized T2D care and cardiometabolic risk reduction. Broader validation in diverse populations, refined implementation strategies, and eventual systematic reviews and meta-analyses are needed.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Atherosclerosis III: Management
Coronary Artery Disease I: Introduction
Coronary Artery Disease IV: Preventive Measures

